Four ANCA vasculitis phenotypes, and one of them may prefer rituximab

Design

multicentre retrospective cohort with ensemble clustering, derivation and validation registries, CART replication

Population

726 Japanese patients with newly diagnosed microscopic polyangiitis or granulomatosis with polyangiitis

Primary outcome

reproducible organ-involvement phenotypes and their association with survival, relapse and induction response

Effect

four replicated clusters with differing survival and relapse; ENT-dominant cluster had favourable survival, higher relapse risk and a non-significant trend favouring rituximab

Two nationwide Japanese registries — J-CANVAS for derivation, JPVAS for validation — provided 726 patients with newly diagnosed microscopic polyangiitis or granulomatosis with polyangiitis. Ensemble clustering was applied to organ involvement data from the Birmingham Vasculitis Activity Score plus additional manifestations, then the clusters were reproduced using classification and regression trees across both cohorts.

Four phenotypes emerged and replicated: renal-dominant without interstitial lung disease, renal-dominant with interstitial lung disease, systemic multi-organ, and ENT-dominant. Survival and relapse incidence differed across them. The ENT-dominant cluster had favourable survival but higher relapse risk, and showed a trend toward better relapse-free survival with rituximab than cyclophosphamide — notably including among myeloperoxidase-ANCA-positive patients, who are conventionally the group in whom rituximab's advantage is assumed to be smaller.

That last observation is the interesting one and also the weakest. It is a trend, in a subgroup, in retrospective registry data where treatment was not randomised — clinicians chose rituximab for reasons the analysis cannot see. What the clustering does support more firmly is that organ pattern carries prognostic information that serotype and the MPA/GPA label do not, which is an argument for describing the phenotype in the notes alongside the serology.

• Record the organ involvement pattern explicitly, not just the MPA or GPA label and serotype
• Expect higher relapse risk with ENT-dominant disease and plan surveillance accordingly
• Flag renal-dominant disease with interstitial lung disease as a distinct prognostic group
• Do not switch to rituximab on the basis of this trend alone in MPO-positive disease
• Use the phenotype to set follow-up intensity rather than to select induction therapy

Why it matters

It gives a prognostic axis in a disease where the conventional subtypes and serotypes explain less than clinicians assume.

Don't overread it

Retrospective registry data; the rituximab advantage in the ENT-dominant cluster is a non-significant trend with confounding by indication.

The statistics, in plain English

Clustering finds structure in whatever data you give it; the reassurance here is that the four clusters reproduced in a separate validation registry, which many clustering studies cannot manage. The rituximab finding is described as a trend, meaning it did not reach conventional significance, and in non-randomised data treatment choice reflects clinician judgement about the patient, not just the phenotype.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.